RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naive Patients with Type 2 Diabetes: A Randomized Controlled Trial.

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naive Patients with Type 2 Diabetes: A Randomized Controlled Trial.

Add to Collection
2016 Others Fist_Author_Year_PM

Full Author : ['Kumar, Ajay', 'Franek, Edward', 'Wise, Jonathan', 'Niemeyer, Marcus', 'Mersebach, Henriette', 'Simo, Rafael']
Journal Title : PloS one
Chapter : Section3
Journal Year : 2016
Cited by : Not Available

PURPOSE: The efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily (OD) compared with insulin glargine U100 (IGlar) OD over 52 weeks in insulin-naive adults with type 2 diabetes mellitus (T2DM) was investigated. METHODS: In this open.....

Keywords : ["oncedaily insulin degludecinsulin aspart versus insulin glargine", "randomized control trial", "type diabetes", "insulinnaive patient", "week", "safety", "efficacy"]